Zynerba Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Zynerba Pharmaceuticals has a total shareholder equity of $29.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $40.5M and $11.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$35.97m |
| Equity | US$29.02m |
| Total liabilities | US$11.46m |
| Total assets | US$40.48m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 6ZY's short term assets ($39.3M) exceed its short term liabilities ($11.5M).
Long Term Liabilities: 6ZY has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 6ZY is debt free.
Reducing Debt: 6ZY had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6ZY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6ZY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 0.5% each year